Should I buy or sell BridgeBio Pharma stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BridgeBio Pharma in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BBIO shares. View BBIO analyst ratings or view top-rated stocks .

What is BridgeBio Pharma's stock price target for 2024?

11 analysts have issued 1-year target prices for BridgeBio Pharma's stock. Their BBIO share price targets range from $33.00 to $70.00. On average, they anticipate the company's share price to reach $47.17 in the next twelve months. This suggests a possible upside of 89.3% from the stock's current price. View analysts price targets for BBIO or view top-rated stocks among Wall Street analysts .

How have BBIO shares performed in 2024?

BridgeBio Pharma's stock was trading at $40.37 at the beginning of 2024. Since then, BBIO stock has decreased by 38.3% and is now trading at $24.92. View the best growth stocks for 2024 here .

Are investors shorting BridgeBio Pharma?

BridgeBio Pharma saw a increase in short interest in March. As of March 31st, there was short interest totaling 14,280,000 shares, an increase of 6.5% from the March 15th total of 13,410,000 shares. Based on an average daily volume of 1,730,000 shares, the short-interest ratio is currently 8.3 days. Approximately 10.3% of the shares of the stock are short sold. View BridgeBio Pharma's Short Interest .

When is BridgeBio Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our BBIO earnings forecast .

How were BridgeBio Pharma's earnings last quarter?

BridgeBio Pharma, Inc. (NASDAQ:BBIO) posted its quarterly earnings results on Thursday, February, 22nd. The company reported ($0.96) earnings per share for the quarter, missing analysts' consensus estimates of ($0.87) by $0.09. The company had revenue of $1.74 million for the quarter, compared to analysts' expectations of $4.78 million. The company's revenue for the quarter was down 8.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.92) EPS.

What ETFs hold BridgeBio Pharma's stock?

ETFs with the largest weight of BridgeBio Pharma (NASDAQ:BBIO) stock in their portfolio include WisdomTree BioRevolution Fund (WDNA) , Virtus LifeSci Biotech Products ETF (BBP) , Principal Healthcare Innovators ETF (BTEC) , SPDR S&P Biotech ETF (XBI) , Direxion Daily S&P Biotech Bull 3x Shares (LABU) , First Trust Small Cap Growth AlphaDEX Fund (FYC) , Principal U.S. Small-Cap Multi-Factor ETF (PSC) and Invesco Nasdaq Biotechnology ETF (IBBQ) .

What other stocks do shareholders of BridgeBio Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BridgeBio Pharma investors own include Advanced Micro Devices (AMD) , Gilead Sciences (GILD) , Cisco Systems (CSCO) , Johnson & Johnson (JNJ) , Pfizer (PFE) , Roku (ROKU) , Editas Medicine (EDIT) , Block (SQ) , Sorrento Therapeutics (SRNE) and Sarepta Therapeutics (SRPT) .

When did BridgeBio Pharma IPO?

BridgeBio Pharma (BBIO) raised $225 million in an initial public offering on Thursday, June 27th 2019. The company issued 15,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR served as the underwriters for the IPO and Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James were co-managers.

Who are BridgeBio Pharma's major shareholders?

BridgeBio Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Portman Square Capital LLP (0.00%), Hennion & Walsh Asset Management Inc. (0.08%), Diversified Trust Co (0.02%) and First Bank & Trust (0.00%). Insiders that own company stock include Brian C Stephenson , Douglas A Dachille , Frank Mccormick , Global Investors Lp Viking, Hannah Valantine , Neil Kumar , Randal W Scott , Richard H Scheller and Ronald J Daniels . View institutional ownership trends .

How do I buy shares of BridgeBio Pharma?

Shares of BBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BBIO

BridgeBio Pharma (BBIO) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free BBIO Stock Alerts

$24.95

-0.03 (-0.12%)

(As of 05:32 PM ET)

Compare

Today's Range: $24.77
▼
$25.52
50-Day Range: $24.98
▼
$39.23
52-Week Range: $12.75
▼
$44.32

Volume: 2.23 million shs
Average Volume: 1.76 million shs
Market Capitalization: $4.39 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $47.17

Get BridgeBio Pharma alerts:

BridgeBio Pharma MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.82 Rating Score
Upside/Downside: 89.3% Upside
$47.17 Price Target
Short Interest: Bearish
10.29% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.31
Upright™ Environmental Score
News Sentiment: 0.48
Based on 5 Articles This Week
Insider Trading: Selling Shares
$85,000 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.09) to ($2.76) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.41 out of 5 stars

Medical Sector

99th out of 919 stocks

Pharmaceutical Preparations Industry

28th out of 415 stocks

4.4

Analyst's Opinion

Consensus Rating
BridgeBio Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
BridgeBio Pharma has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
10.29% of the float of BridgeBio Pharma has been sold short.
Short Interest Ratio / Days to Cover
BridgeBio Pharma has a short interest ratio ("days to cover") of 8.3.
Change versus previous month
Short interest in BridgeBio Pharma has recently increased by 6.49%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
BridgeBio Pharma does not currently pay a dividend.
Dividend Growth
BridgeBio Pharma does not have a long track record of dividend growth.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
BridgeBio Pharma has received a 53.04% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Infigratinib", "Fosdenopterin", and "Clinical research services for cancer" products. See details.
Environmental Sustainability
The Environmental Impact score for BridgeBio Pharma is -2.31.

1.9

News and Social Media Coverage

News Sentiment
BridgeBio Pharma has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for BridgeBio Pharma this week, compared to 5 articles on an average week.
Search Interest
39 people have searched for BBIO on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
MarketBeat Follows
Only 13 people have added BridgeBio Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -7% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BridgeBio Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $85,000.00 in company stock.
Percentage Held by Insiders
28.52% of the stock of BridgeBio Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
99.85% of the stock of BridgeBio Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for BridgeBio Pharma are expected to grow in the coming year, from ($3.09) to ($2.76) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BridgeBio Pharma is -6.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BridgeBio Pharma is -6.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About BridgeBio Pharma Stock (NASDAQ:BBIO)

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

BBIO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BBIO Stock News Headlines

April 17, 2024 | americanbankingnews.com

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Short Interest Update

April 14, 2024 | americanbankingnews.com

BridgeBio Pharma (NASDAQ:BBIO) Stock Price Down 5.7%

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 11, 2024 | finance.yahoo.com

BridgeBio Pharma, Inc. (BBIO)

April 10, 2024 | globenewswire.com

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

April 10, 2024 | globenewswire.com

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

April 8, 2024 | markets.businessinsider.com

Buy Rating Affirmed for BridgeBio Pharma on Acoramidis’ Positive ATTR-CM Trial Outcomes

April 7, 2024 | globenewswire.com

BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 25, 2024 | markets.businessinsider.com

Buy Rating Justified for BridgeBio Pharma Amidst Promising Long-Term Market Prospects for ATTR-CM Treatments

March 22, 2024 | seekingalpha.com

BridgeBio Pharma: Assessing Acoramidis' Market Opportunity, Further Upside Potential Evident

March 20, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Jazz Pharmaceuticals (JAZZ)

March 20, 2024 | globenewswire.com

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

March 19, 2024 | finance.yahoo.com

BBIO Mar 2024 32.000 call

March 17, 2024 | nasdaq.com

Validea Detailed Fundamental Analysis - BBIO

March 16, 2024 | finance.yahoo.com

BBIO Mar 2024 30.000 call

March 16, 2024 | ca.finance.yahoo.com

BBIO Mar 2024 30.000 put

March 9, 2024 | finance.yahoo.com

BBIO Mar 2024 25.000 put

March 9, 2024 | ca.finance.yahoo.com

BBIO Mar 2024 31.000 call

March 7, 2024 | ca.finance.yahoo.com

BBIO Mar 2024 25.000 call

March 6, 2024 | uk.investing.com

BridgeBio Pharma launches $250 million stock offering

March 6, 2024 | msn.com

BridgeBio prices $250M stock offering

March 6, 2024 | markets.businessinsider.com

BridgeBio Pharma Prices Offering Of $250 Mln Of Shares

March 5, 2024 | globenewswire.com

BridgeBio Pharma Announces Pricing of Public Offering of Common Stock

March 5, 2024 | finance.yahoo.com

BBIO Mar 2024 31.000 put

March 5, 2024 | nasdaq.com

BridgeBio Pharma Commences Public Offering Of $250 Mln Of Shares; Stock Down

March 4, 2024 | markets.businessinsider.com

Maintained Buy Rating for BridgeBio Pharma Amidst Strategic Partnerships and Market Growth Potential

See More Headlines

Receive BBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BridgeBio Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/22/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:BBIO
CUSIP: N/A
CIK: 1743881
Web: bridgebio.com
Phone: (650) 391-9740
Fax: N/A
Employees: 550
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $47.17
High Stock Price Target: $70.00
Low Stock Price Target: $33.00
Potential Upside/Downside: +86.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.82
Research Coverage: 11 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.94)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-643,200,000.00
Net Margins: -6,913.92%
Pretax Margin: -7,021.94%
Return on Equity: N/A
Return on Assets: -110.39%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.32
Quick Ratio: 3.32

Sales & Book Value

Annual Sales: $9.30 million
Price / Sales: 477.39
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($7.72) per share
Price / Book: -3.27

Miscellaneous

Outstanding Shares: 175,830,000
Free Float: 125,685,000
Market Cap: $4.44 billion
Optionable: Optionable
Beta: 1.03

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Dr. Neil Kumar Ph.D. (Age 45)
Co-Founder, President, CEO & Director
Comp: $2.1M
Dr. Charles J. Homcy M.D. (Age 76)
Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director
Comp: $208k
Dr. Brian C. Stephenson C.F.A. (Age 43)
Ph.D., CFO & Secretary
Comp: $1.15M
Dr. Richard H. Scheller Ph.D. (Age 71)
Chairman of Research & Development
Comp: $202.4k
Dr. Frank P. McCormick Ph.D. (Age 74)
Co-Founder, Chairman of Oncology & Director
Dr. Uma Sinha Ph.D. (Age 66)
Chief Scientific Officer
Comp: $1.31M
Grace Rauh
Vice President of Communications
Mr. Eli M. Wallace Ph.D. (Age 57)
Chief Scientific Officer of Oncology
Dr. Thomas Trimarchi Ph.D.
Chief Product Officer
Dr. Eric Michael David J.D. (Age 52)
M.D., Ph.D., Chief Executive Officer of Gene Therapy

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BBIO Stock Analysis - Frequently Asked Questions

Should I buy or sell BridgeBio Pharma stock right now?: 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BridgeBio Pharma in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BBIO shares.
View BBIO analyst ratings or view top-rated stocks.
What is BridgeBio Pharma's stock price target for 2024?: 11 analysts have issued 1-year target prices for BridgeBio Pharma's stock. Their BBIO share price targets range from $33.00 to $70.00. On average, they anticipate the company's share price to reach $47.17 in the next twelve months. This suggests a possible upside of 89.3% from the stock's current price.
View analysts price targets for BBIO or view top-rated stocks among Wall Street analysts.
How have BBIO shares performed in 2024?: BridgeBio Pharma's stock was trading at $40.37 at the beginning of 2024. Since then, BBIO stock has decreased by 38.3% and is now trading at $24.92.
View the best growth stocks for 2024 here.
Are investors shorting BridgeBio Pharma?: BridgeBio Pharma saw a increase in short interest in March. As of March 31st, there was short interest totaling 14,280,000 shares, an increase of 6.5% from the March 15th total of 13,410,000 shares. Based on an average daily volume of 1,730,000 shares, the short-interest ratio is currently 8.3 days. Approximately 10.3% of the shares of the stock are short sold.
View BridgeBio Pharma's Short Interest.
When is BridgeBio Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our BBIO earnings forecast.
How were BridgeBio Pharma's earnings last quarter?: BridgeBio Pharma, Inc. (NASDAQ:BBIO) posted its quarterly earnings results on Thursday, February, 22nd. The company reported ($0.96) earnings per share for the quarter, missing analysts' consensus estimates of ($0.87) by $0.09. The company had revenue of $1.74 million for the quarter, compared to analysts' expectations of $4.78 million. The company's revenue for the quarter was down 8.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.92) EPS.

What ETFs hold BridgeBio Pharma's stock?: ETFs with the largest weight of BridgeBio Pharma (NASDAQ:BBIO) stock in their portfolio include WisdomTree BioRevolution Fund (WDNA), Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), First Trust Small Cap Growth AlphaDEX Fund (FYC), Principal U.S. Small-Cap Multi-Factor ETF (PSC) and Invesco Nasdaq Biotechnology ETF (IBBQ).
What other stocks do shareholders of BridgeBio Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BridgeBio Pharma investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Pfizer (PFE), Roku (ROKU), Editas Medicine (EDIT), Block (SQ), Sorrento Therapeutics (SRNE) and Sarepta Therapeutics (SRPT).
When did BridgeBio Pharma IPO?: BridgeBio Pharma (BBIO) raised $225 million in an initial public offering on Thursday, June 27th 2019. The company issued 15,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR served as the underwriters for the IPO and Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James were co-managers.
Who are BridgeBio Pharma's major shareholders?: BridgeBio Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Portman Square Capital LLP (0.00%), Hennion & Walsh Asset Management Inc. (0.08%), Diversified Trust Co (0.02%) and First Bank & Trust (0.00%). Insiders that own company stock include Brian C Stephenson, Douglas A Dachille, Frank Mccormick, Global Investors Lp Viking, Hannah Valantine, Neil Kumar, Randal W Scott, Richard H Scheller and Ronald J Daniels.
View institutional ownership trends.
How do I buy shares of BridgeBio Pharma?: Shares of BBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BBIO) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

BridgeBio Pharma (BBIO) Stock Price, News & Analysis

BridgeBio Pharma MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About BridgeBio Pharma Stock (NASDAQ:BBIO)

BBIO Stock Price History

BBIO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

BBIO Stock Analysis - Frequently Asked Questions

Overall MarketRank^™